A blood-test clue: mitochondrial DNA copy number separates Parkinson’s from a look-alike disorder

Telling Parkinson’s disease apart from multiple system atrophy — a rarer neurodegenerative disorder that mimics it early on — is one of neurology’s hardest calls, and the wrong diagnosis can mean years of the wrong treatment. A new study suggests a clue may be hiding in a simple blood draw: the number of copies of mitochondrial DNA circulating in blood.

What did the researchers measure?

Using quantitative PCR on blood samples, the team measured mitochondrial DNA copy number at the ND1 gene in three groups: Parkinson’s patients, healthy controls, and patients with multiple system atrophy. Parkinson’s patients had significantly lower mtDNA copy number than healthy controls — and, critically, significantly lower than the multiple system atrophy group too. The analyses adjusted for age and sex and survived false-discovery-rate correction.

The practical appeal: this is a blood test, not a muscle biopsy or a brain scan. If validated, it could give neurologists an objective molecular measurement to weigh alongside clinical judgment.

How close is this to a real test?

Not close yet. This is case-control observational data — a snapshot comparing groups, not a prospective trial showing the measurement can diagnose new patients correctly. Biomarkers that look clean in case-control studies often blur when tested in the messy real world of early, uncertain diagnoses — exactly the patients who need the test most.

It also needs replication in independent cohorts, standardization of the assay, and proof that it adds value beyond what a good neurologist already does. Those are years of work, not months.

Why mitochondria keep showing up in brain disease

Parkinson’s has been a mitochondrial disease since before the term was fashionable — the toxins that cause parkinsonism poison mitochondrial complex I, and inherited Parkinson’s genes (PINK1, Parkin) run the mitochondrial cleanup system. That a blood measure of mitochondrial genome abundance tracks the disease is biologically coherent, even if the test itself is unproven.

For readers: this is a research lead worth watching, not a test to ask your doctor for. No clinic should be selling you an “mtDNA copy number” Parkinson’s screen today.

Where the evidence stands

• Established: Mitochondrial dysfunction is central to Parkinson’s biology (complex I toxins, PINK1/Parkin mitophagy genes); distinguishing Parkinson’s from multiple system atrophy clinically is genuinely difficult.
• Preliminary: The mtDNA copy-number difference is case-control observational data; it needs prospective validation and independent replication.
• Absent: No validated clinical test exists; no evidence it improves real-world diagnostic accuracy yet.